Santhera Signs an Exclusive License Agreement with Chiesi to Develop and Commercialize Raxone for Leber’s Hereditary Optic Neuropathy

Santhera Signs an Exclusive License Agreement with Chiesi to Develop and Commercialize Raxone for Leber’s Hereditary Optic Neuropathy

Shots:

  • Santhera to receive $49.5M upfront, ~$54.5M as milestones, making the total deal value ~104M. Chiesi to get an exclusive WW rights to develop & commercialize Raxone for LHON and other ophthalmological indications (Ex- the US & Canada) and has an option to fully acquire Santhera’s Raxone business
  • The focus of the agreement is to allow Santhera to advance its clinical-stage neuro-muscular and pulmonary programs. The transaction is expected to close in Q3’19
  • Raxone (idebenone) is a therapy for visual impairment in adults and adolescents aged ≥12 yrs with LHON and has received ODD in 2017. Additionally, Santhera plans to submit Puldysa’s (idebenone) MAA to EMA for DMD

Click here to read full press release/ article | Ref: Santhera | Image: Bianco Lavoro